- Home
- FENC vs VYGR Comparison
FENC vs VYGR Comparison
Compare FENC & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | VYGR |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.5M | 232.4M |
| IPO Year | 2001 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FENC | VYGR |
|---|---|---|
| Price | $7.57 | $4.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $13.50 | ★ $17.00 |
| AVG Volume (30 Days) | 196.5K | ★ 469.2K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $38,790,000.00 | $31,316,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $75.22 | $71.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.68 | $2.65 |
| 52 Week High | $9.92 | $6.55 |
Technical Indicators
Market Signals| Indicator | FENC | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 42.20 | 54.46 |
| Support Level | $7.35 | $3.74 |
| Resistance Level | $7.74 | $4.51 |
| Average True Range (ATR) | 0.36 | 0.21 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 20.00 | 84.94 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.